Core Viewpoint - Novartis plans to build a radioligand therapy manufacturing site in Texas, marking its first facility of this kind in the state and the fifth in the U.S. [1][4] Group 1: Investment and Expansion - The investment is part of Novartis' broader strategy to spend $23 billion on building and expanding facilities in the U.S. [2] - The new Texas site will enhance Novartis' manufacturing capacity in response to increased domestic demand and regulatory pressures [2][3]. Group 2: Facility Details - The new facility will cover 46,000 square feet and is expected to be fully operational by 2028 [4]. - The site will create jobs in bioengineering, advanced manufacturing, quality, and operations [4]. Group 3: Product Focus - Radioligand therapy is a targeted cancer treatment that delivers radiation directly to tumor cells, with Novartis already marketing Pluvicto and Lutathera for specific cancers [4]. - The addition of this facility will strengthen Novartis' ability to meet the growing demand for next-generation cancer treatments [3].